The viral vector and plasmid DNA manufacturing market offers growth opportunities in gene therapies, contract manufacturing, and emerging markets like Asia-Pacific. Key trends include rising demand ...
In the development of DNA vaccines and cell and gene therapies, manufacturing plasmid DNA creates a crucial bottleneck. Such a slowdown could intensify with the market for manufacturing DNA plasmids ...
The globe viral vectors & plasmid DNA manufacturing market size is expected to be lead USD 29.82 billion by 2035, increasing ...
ZHENJIANG, China, Dec. 7, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio ...
Molecular biology is an ever-changing field, and most significant developments have happened because of changes in plasmid DNA sequencing. A plasmid, a circular and small double-stranded DNA entity ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and ...
DNA vaccines, wherein a new antigen is inserted into a validated vector, have tremendous potential for deployment in pandemic applications as they can be rapidly produced in a validated, ...
Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.
This study is led by Prof. Qunxin She (Shandong University) and Dr. Guanhua Yuan (Shandong University). The research group has constructed versatile genetic tools for Saccharolobus islandicus REY15A, ...
Off-the-shelf pHelper simplifies gene therapy supply chains with immediate availability WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results